Ekiwandiiko kyonna ekituumiddwa Retatrutid Dosage Guide & Titration Schedule 2026 kyetaaga okutandika n’okunnyonnyola okumu okukulu: mu 2026, retatrutide ekyali peptide efuyiddwa omulundi gumu buli wiiki enoonyereza, so si ddagala erikkirizibwa nga liriko akabonero akalaga nti liwandiikiddwa mu lujjudde. Lilly agiyogerako nga triple hormone receptor agonist egenderera GIP, GLP-1, ne glucagon receptors, era agamba nti mu mateeka efunibwa bokka abeetabye mu kugezesebwa kwayo okw’obujjanjabi. Lilly Medical era egamba nti mu kiseera kino eddagala lya retatrutide terikkirizibwa mu nsi yonna oba mu bitundu byonna. Ekyo kitegeeza nti 'obulagirizi bw'eddagala' obusinga obutuufu leero si lupapula lw'ebiragiro ku nkozesa y'abakozesa, wabula mu bufunze n'obwegendereza enteekateeka z'okugereka, ddoozi ezigendereddwamu, n'engeri z'okugumiikiriza ezikozesebwa mu kunoonyereza okw'obujjanjabi. Ku basomi abagoberera enkulaakulana ya peptide, emitendera gy’okugula, oba amawulire agakwata ku bikozesebwa eby’ekikugu, enjawulo eyo nsonga kubanga emboozi mu 2026 ekwata ku kugezesa okulinnyisa ddoozi, so si kukozesa okweragirira.
Retatrutid esukkulumye ku kucamuka mu ntandikwa n’eyingira mu nteekateeka empanvu ey’okukulaakulanya Omutendera ogw’okusatu. Lilly yategeeza mu March 2026 nti okunoonyereza kwayo okwasooka okwa Phase 3 type 2 diabetes, TRANSCEND-T2D-1, kwatuukiriza enkomerero zaayo ezisookerwako n’ezikulu ez’okubiri, ate nga okusoma okwasooka okwa Phase 3 okwekuusa ku mugejjo nga TRIUMPH-4 kwalaga dda ebivudde mu kugejja eby’amaanyi. Wadde kiri kityo, Lilly akyagenda mu maaso n’okunnyonnyola retatrutide ng’okunoonyereza, era okunoonyereza okugenda mu maaso kukyakebera engeri ddoozi ez’enjawulo gye zikolamu mu mugejjo, sukaali ow’ekika eky’okubiri, obulwadde bw’amagumba mu kugulu, okuziyiza okussa mu tulo, ebiva mu misuwa gy’omutima, ebiva mu kibumba, n’embeera z’endwadde ezeekuusa ku kibumba.
Kino kikulu eri okukubaganya ebirowoozo ku ddoozi kubanga tewali ddoozi emu ekkirizibwa ey’okuddaabiriza n’okutuusa kati. Wabula, ekifaananyi kya 2026 kizimbibwa okwetoloola dose Lilly z’akola ennyo ng’ayita mu Phase 3: 4 mg, 9 mg, ne 12 mg, zonna ziweebwa omulundi gumu buli wiiki oluvannyuma lw’okugenda mu maaso mpolampola.
Mu kukubaganya ebirowoozo ku peptide ku mutimbagano, ebirimu mu ddoozi bitera okwanguyirwa mu chati ezirabika nga ziteredde okusinga ssaayansi bw’ali. Nga olina retatrutide, ekyo kibuzaabuza. Lilly alabula mu bulambulukufu nti molekyu eno tezzeemu kwekenneenyezebwa oba okukkirizibwa ekitongole kyonna ekifuga era agamba nti tewali muntu yenna yandirowoozezza ku kutwala kintu kyonna kigamba nti kya retatrutide ebweru w’okugezesebwa kw’obujjanjabi okuyambibwako Lilly. Ekitongole kya FDA era kirabudde abaguzi ku bintu ebitakkirizibwa ebirimu eddagala lya retatrutide ebitundibwa nga biriko ebiragiro ebikwata ku ddoozi, nga kitegedde nti ebintu ng’ebyo biyinza okuba eby’omutindo ogutamanyiddwa era nga biyinza okuba eby’obulabe.
Kale, eri abasomi ba SEO n’abaguzi b’amakolero bonna, framing evunaanyizibwa eri eno: retatrutide dosage mu 2026 kitegeeza okunoonyereza clinical trial dosing, so si retail oba routine prescription dosing. Ekyo era kinnyonnyola lwaki amawulire agasinga okwesigika gava mu bifulumiziddwa Lilly, ebikozesebwa mu Lilly Medical, enkalala za ClinicalTrials.gov, n’ebitabo by’okugezesa ebikebereddwa bannaabwe okusinga chati ezikoleddwa abatunzi.
Enkola y’okukozesa eddagala erisinga okutegeerekeka mu 2026 eva mu bintu bya Lilly ebya Phase 3. Mu TRANSCEND-T2D-1, abeetabye mu kugezesebwa ku retatrutide baatandika ku 2 mg omulundi gumu buli wiiki era ne beeyongera mu nkola ey’emitendera buli luvannyuma lwa wiiki nnya okutuusa lwe baatuuka ku ddoozi gye baali bategese. Lilly yannyonnyola omusingi gwe gumu omukulu ogw’okulinnyisa omutindo mu nteekateeka yonna ey’omugejjo eya TRIUMPH nayo.
Ekyo kivaamu ensengeka ya titration eyesigamiziddwa ku kugezesebwa entuufu:
Dozi egenderere |
Wiiki 1–4 |
Wiiki 5–8 |
Wiiki 9–12 |
Wiiki 13–16 |
Wiiki 17 okudda waggulu |
4 mg |
2 mg |
4 mg |
okukuuma |
— |
— |
9 mg |
2 mg |
4 mg |
6 mg |
9 mg |
okukuuma |
12 mg |
2 mg |
4 mg |
6 mg |
9 mg |
12 mg |
Omulongooti guno gufunza enteekateeka z’okulinnyisa omutindo Lilly ze yaloopa ku ddoozi ezigendereddwamu ez’omutendera ogw’okusatu. Mu ngeri endala, omukono gwa 4 mg gukozesa omutendera gumu ogw’okulinnyisa oluvannyuma lw’omutendera gw’okutandika, omukono gwa 9 mg gukozesa emitendera gya ddoozi esatu nga tegunnaba kuddaabiriza, ate omukono gwa 12 mg gukozesa ena. Dizayini ezimbiddwa bulungi okulongoosa okugumiikiriza okusinga okufubutuka abeetabye mu kugezesebwa okutuuka ku kukwatibwa okusinga.
Okunoonyereza kwa Retatrutid okwa Phase 2 ku mugejjo kukyali kukulu kubanga kwalaga lwaki okulonda ddoozi kwafuuka ensonga enkulu bwetyo. Lilly yategeeza nti mu bantu abakulu abagejjulukuka oba abagejjulukuka abatalina sukaali, retatrutide yatuuka ku kukendeera kw’obuzito okutuuka ku bitundu 17.5% ku wiiki 24 ate okutuuka ku bitundu 24.2% ku wiiki 48. Ekitabo kya New England Journal of Medicine era kiraga nti okunoonyereza kuno kwanoonyereza ku mikono egya ddoozi ya retatrutide eziwera okusinga ekkubo erimu eritali ddene, omuli ebibinja ebya ddoozi entono n’eya waggulu.
Phase 2 kye yakyuka ddala kwe kutegeera kw’akatale ku dose-response. Emikono egya ddoozi esingako gyakola obubonero obw’amaanyi obw’okugejja, naye ebizibu eby’omu lubuto nabyo byali byetoolodde okulinnyisa ddoozi. Eyo y’emu ku nsonga lwaki enkulaakulana oluvannyuma yagenda mu ndowooza ya titration etegekeddwa obulungi mu kifo ky’okutwala retatrutide ng’ekintu eky’enjawulo eky’obuzito obutakyukakyuka.
Ensobi etera okukolebwa mu kutunda ebirimu peptide kwe kussa essira ku ddoozi esembayo yokka. Nga olina retatrutide, ekkubo erigenda ku ddoozi kumpi likulu nnyo ng’omuwendo gwennyini. Mu 2026 Lilly’s Phase 3 diabetes release, ebizibu ebisinga okuvaamu byali kuziyira, ekiddukano, n’okusiiyibwa, era Lilly yategeeza nti okusinga byaliwo mu kiseera ddoozi egenda erinnya. Ekintu ekyo kikulu nnyo kubanga kinnyonnyola ensonga eri emabega wa ddoozi etandika eya 2 mg n’obudde obw’okulinnya mu wiiki nnya.
Enkola y’emu erabika mu TRIUMPH-4. Lilly yategeeza nti waliwo ebizibu ebiva mu lubuto ng’okuziyira, ekiddukano, okuziyira, okusiiyibwa, n’okukendeeza ku njagala y’okulya, wamu n’okubulwa omubiri mu bamu ku beetabye mu kutendekebwa kuno. Okuyimiriza olw’ebizibu ebibaddewo kwali kungi mu bibinja bya 9 mg ne 12 mg okusinga placebo, era Lilly yagamba nti okuyimiriza okwo kwalina akakwate nnyo ne BMI eyasooka, ng’okulekera awo okumu kwekuusa ku kulowoozebwa nti okugejja okuyitiridde.
Dozi essatu ezigendererwamu ezisinga okulabika mu 2026 ze zino: 4 mg, 9 mg, ne 12 mg. Bonna tebalabika mu buli muwendo gw’abantu abanoonyereza mu ngeri y’emu. Mu TRANSCEND-T2D-1, Lilly yategeeza nti A1C yakendeera ku wiiki 40 nga ya -1.7% ku 4 mg, -2.0% ku 9 mg, ne -1.9% ku 12 mg, ate okukendeeza ku buzito bw’omubiri kwali -11.5%, -15.5%, ne -16.8%.
Mu mulimu gwa Phase 3 ogutunuulidde omugejjo, Lilly abadde assa nnyo essira ku ddoozi eza waggulu. Mu TRIUMPH-4, ebibinja bya 9 mg ne 12 mg byavaamu okukendeera kw’obuzito bw’omubiri okwa -26.4% ne -28.7% ku wiiki 68 mu bantu abakulu abalina omugejjo oba abagejjulukuka n’obulwadde bw’amagumba g’okugulu. Lilly era yategeezezza nti ebivudde mu TRIUMPH ebirala ebisuubirwa mu 2026 mulimu ddoozi y’okulabirira eya 4 mg ku mabbali ga ddoozi 9 mg ne 12 mg ezaalambikibwa edda mu kunoonyereza okwo.
Okutwalira awamu, data zino ziraga enzikiriziganya y’enkulaakulana eya 2026 nga 4 mg eyinza okukola ng’enkola ey’okulabirira ey’amaanyi amatono, ate 9 mg ne 12 mg bye biruubirirwa by’okunoonyereza ebisinga okubeera eby’amaanyi ebisomesebwa ng’ebikosa ebinene eby’okugejja bye biri wakati. Ekyo ntaputa eyesigamiziddwa ku nteekateeka y’okugezesa ne data y’omutendera ogw’oku ntikko, so si tteeka erikkirizibwa eriwandiika.
Ku basomi abagezaako okutegeera enteekateeka ya retatrutide titration mu bigambo ebitegeerekeka, enkola y’okugezesa ekwatagana bulungi:
Okunoonyereza okusinga ku mutendera ogusembayo kutandika ne 2 mg omulundi gumu buli wiiki.
Dozi yeeyongera buli luvannyuma lwa wiiki nnya, ebiseera ebisinga eyita mu mitendera egy’omu makkati nga 4 mg, 6 mg, ne 9 mg mu kkubo okutuuka ku kiruubirirwa eky’oku ntikko.
Ekiruubirirwa ekiweereddwa bwe kituuka, okutwalira awamu abeetabye basigala awo okumala ekiseera kyonna eky’obujjanjabi okuggyako nga enkola ekkiriza okutaataaganyizibwa oba okukyusa mu ddoozi. Ebikozesebwa bya Lilly bino byogera ng’okulinnyisa emitendera okutuuka ku ddoozi egenderere nga kigobererwa okugenda mu maaso n’obujjanjabi ku ddaala eryo.
Retatrutid y’emu ku peptides ezisinga okutunuulirwa ennyo mu metabolic peptides mu 2026, naye emboozi yaayo ey’eddagala ekyali mboozi ya mutendera gwa nkulaakulana, so si ya bya busuubuzi ewedde. Obujulizi obusinga amaanyi obuliwo leero bulaga nti enkola y’empiso buli wiiki etandikira ku 2 mg, n’egenda yeeyongera buli luvannyuma lwa wiiki nnya, era ng’egenderera ku ddoozi ezigendereddwamu nga 4 mg, 9 mg, oba 12 mg okusinziira ku nkola. Ebizuuliddwa mu mutendera 2 n’omutendera 3 biyamba okunnyonnyola lwaki ensengeka eyo eriwo: ddoozi eza waggulu zirabika nga zivuga obubonero obw’amaanyi obw’obulungi, so ng’ate ekiseera ky’okulinnyisa omutindo kye kisinga obukulu okugumiikiriza. Okusinziira ku ndowooza yaffe, ekyo kifuula okutaputa n’obwegendereza okuba okw’omuwendo okusinga hype. Ku basomi, ttiimu ezinoonya ensibuko, n’abaguzi b’amakolero abaagala okutegeera ebikozesebwa mu retatrutide, ebikwata ku peptide, n’enkula y’eby’ekikugu egazi mu ngeri esinga okubeera ey’omusingi, kirungi okuyiga ebisingawo okuva Cocer Peptides Co., Ltd. n’okukubaganya ebirowoozo ku mulamwa okuva mu ndowooza eyesigamiziddwa ku bujulizi, amawulire agakwata ku bikozesebwa okusinga endowooza y’okukozesa eddagala mu ngeri ennyangu.
Nedda Lilly agamba nti retatrutide ya kunoonyereza, efunibwa mu mateeka okuyita mu kugezesebwa kwayo kwokka, era tekkirizibwa bitongole bifuga.
Enkola ya Phase 3 esinga okutegeerekeka obulungi eyaloopebwa Lilly etandika abeetabye ku 2 mg omulundi gumu buli wiiki, n’eddirirwa okweyongera mu mitendera buli luvannyuma lwa wiiki nnya okutuusa nga ddoozi egenderere eyaweebwa etuuse.
Ebizibu Lilly bye yaloopebwa naddala okuziyira, ekiddukano, n’okusiiyibwa, byasinga kubaawo mu kiseera ky’okulinnyisa ddoozi, y’ensonga lwaki enteekateeka y’okulinnyisa emitendera empola erabika ng’esinga obukulu mu kugumiikiriza.
Yee. ClinicalTrials.gov erimu okunoonyereza mu ngeri ey’enjawulo okwekenneenya enteekateeka ez’enjawulo ez’okulinnyisa ddoozi ya retatrutide, okulaga nti enkola ya titration ekyalongoosebwa.
